Urinary%20incontinence Patient Education

Patient Education

Lifestyle Modification

Fluid Intake

Average amount of fluid needed per day is calculated based on patient’s lean body mass
Encourage patients to modify their fluid intake to produce a 24-hr urinary output between 1-2 L
- A very large or small urine volume output can contribute to urinary incontinence

Diet

Certain foods contain stimulants that may exacerbate symptoms of incontinence
- Heavy or hot spices
- Fruits or juices w/ acidic pH
- Corn syrup, sugar, honey

Use of artificial sweeteners may also contribute to urge incontinence

Caffeine

Studies suggest that decreasing caffeine may improve frequency & urgency
Eg coffee, tea, carbonated drinks & hot chocolate

Weight Loss

In morbidly obese women, massive (surgically induced) weight loss has been shown to significantly decrease incontinence
- Should be considered as first-line treatment

Moderate weight loss may also decrease incontinence

Smoking Cessation

Smoking >20 cigarettes per day is considered to reinforce urinary incontinence

Use of Anti-incontinence Products

Pads & products that help contain urine loss may be beneficial
Absorbent products are temporary means to absorb urine & help protect skin & clothing
- May also be used as adjunct to behavioral & pharmacological treatment

Urethral occlusive products
- Artificial device inserted into or placed over urethral meatus
- Keep patients drier, but more difficult & expensive to use compared to absorbent products

Catheters
- Eg indwelling urethral catheters, suprapubic tubes & intermittent self-catheterization
- Some patients improve w/ temporary continuous Foley catheterization wherein bladder capacity returns to normal & voluntary detrusor function improves
- Intermittent catheterization is the best form of bladder draining for those who are not physically or mentally handicapped

Penile clamps for men
Intravaginal devices for women

Product Highlight - Lanzotred

13 Sep 2023

Enzalutamide 40 mg softcap

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.